文献速递胸部肿瘤放疗

NRG Oncology RTOG 0915(NCCTG N0927)长期随访:比较两种立体定向体部放疗方案治疗医学上无法手术的I期周围型非小细胞肺癌的随机2期研究

Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-12-01

该2期多中心随机研究比较34 Gy单次与48 Gy分4次立体定向体部放疗在医学上无法手术的I期周围型非小细胞肺癌患者中的长期结果,主要终点为1年毒性率。中位随访4.0年,两组≥3级毒性率分别为2.6%与11.1%,5年原发肿瘤失败率、总生存率和无进展生存率相近,中位生存时间分别为4.1年与4.6年。结论认为两方案疗效相似,需更大样本研究检测生存差异。

要点

  • 34 Gy单次与48 Gy分4次两组≥3级毒性率分别为2.6%与11.1%。
  • 5年原发肿瘤失败率34 Gy组10.6% vs 48 Gy组6.8%。
  • 5年总生存率34 Gy组29.6% vs 48 Gy组41.1%,无进展生存率19.1% vs 33.3%。

核心结论

  • 两方案均未观察到晚期毒性增加,5年原发肿瘤控制率组间相似,中位生存时间各约4年提示疗效相似,但需更大样本研究以检测生存差异。

研究设计与样本

  • 随机2期多中心研究,纳入医学上无法手术、活检证实的周围型T1或T2 N0M0非小细胞肺癌患者,主要终点为1年毒性率,次要终点包括失败和生存结局。
  • 研究于2009年9月开放,2011年3月关闭,最终数据分析截至2018年5月17日。
  • 共94例入组,84例符合分析条件:34 Gy单次组39例,48 Gy分4次组45例。

主要发现

  • 全部患者中位随访时间4.0年,分析时存活者中位随访时间6.0年。
  • ≥3级毒性率34 Gy组为2.6%,48 Gy组为11.1%。
  • 中位生存时间34 Gy组4.1年 vs 48 Gy组4.6年。
  • 5年原发肿瘤失败率34 Gy组10.6%(95%CI 3.3%-23.1%) vs 48 Gy组6.8%(95%CI 1.7%-16.9%)。
  • 5年总生存率34 Gy组29.6%(95%CI 16.2%-44.4%) vs 48 Gy组41.1%(95%CI 26.6%-55.1%);5年无进展生存率34 Gy组19.1%(95%CI 8.5%-33.0%) vs 48 Gy组33.3%(95%CI 20.2%-47.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需更大样本研究以检测生存差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To present long-term results of RTOG 0915/NCCTG N0927, a randomized lung stereotactic body radiation therapy trial of 34 Gy in 1 fraction versus 48 Gy in 4 fractions. METHODS AND MATERIALS: This was a phase 2 multicenter study of patients with medically inoperable non-small cell lung cancer with biopsy-proven peripheral T1 or T2 N0M0 tumors, with 1-year toxicity rates as the primary endpoint and selected failure and survival outcomes as secondary endpoints. The study opened in September 2009 and closed in March 2011. Final data were analyzed through May 17, 2018. RESULTS: Eighty-four of 94 patients accrued were eligible for analysis: 39 in arm 1 and 45 in arm 2. Median follow-up time was 4.0 years for all patients and 6.0 years for those alive at analysis. Rates of grade 3 and higher toxicity were 2.6% in arm 1 and 11.1% in arm 2. Median survival times (in years) for 34 Gy and 48 Gy were 4.1 versus 4.6, respectively. Five-year outcomes (95% confidence interval) for 34 Gy and 48 Gy were a primary tumor failure rate of 10.6% (3.3%-23.1%) versus 6.8% (1.7%-16.9%); overall survival of 29.6% (16.2%-44.4%) versus 41.1% (26.6%-55.1%); and progression-free survival of 19.1% (8.5%-33.0%) versus 33.3% (20.2%-47.0%). Distant failure as the sole failure or a component of first failure occurred in 6 patients (37.5%) in the 34 Gy arm and in 7 (41.2%) in the 48 Gy arm. CONCLUSIONS: No excess in late-appearing toxicity was seen in either arm. Primary tumor control rates at 5 years were similar by arm. A median survival time of 4 years for each arm suggests similar efficacy, pending any larger studies appropriately powered to detect survival differences.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Videtic GM, Paulus R, Singh AK, et al. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 30513377. doi:10.1016/j.ijrobp.2018.11.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。